Biologically equivalent substitutive technology: what is needed to manufacture pluripotent stem cells for next-generation platforms for discovery and therapy

Author： De Sousa Paul A  

Publisher： Future Medicine

ISSN： 1746-0751

Source： Regenerative Medicine, Vol.8, Iss.5, 2013-09, pp. : 519-521

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Converging technologies to enable induced pluripotent stem cells in drug discovery

By Flynn Peter   Yingling Jessica   Shoemaker Dan  

Regenerative Medicine, Vol. 5, Iss. 4, 2010-07 ,pp. : 489-491

Future Medicine

Access to resources Recommend Favorite

Induced pluripotent stem cells: an emerging technology platform and the Gartner hype cycle

By Mason Chris   Manzotti Elisa  

Regenerative Medicine, Vol. 4, Iss. 3, 2009-05 ,pp. : 329-331

Future Medicine

Access to resources Recommend Favorite

Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery

By Rowntree Rebecca K   McNeish John D  

Regenerative Medicine, Vol. 5, Iss. 4, 2010-07 ,pp. : 557-568

Future Medicine

Access to resources Recommend Favorite

miRNA in pluripotent stem cells

By Lakshmipathy Uma   Davila Jonathan   Hart Ronald P  

Regenerative Medicine, Vol. 5, Iss. 4, 2010-07 ,pp. : 545-555

Future Medicine

Access to resources Recommend Favorite

Recent Patents in Pluripotent Stem Cells

By  

Recent Patents on Regenerative Medicine, Vol. 5, Iss. 1, 2015-04 ,pp. : 20-26

Bentham Science Publishers

Access to resources Recommend Favorite